|
Market Closed -
Nasdaq
07:00:00 29/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 9.835 USD | -2.62% |
|
+6.79% | +27.40% |
| 16/10 | Verastem's G12D Drug Shows Promise in Pancreatic Cancer, Shares Undervalued, RBC Says | MT |
| 15/10 | Mizuho Raises Price Target on Verastem to $14 From $13, Keeps Outperform Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| VERASTEM, INC. | Bio Therapeutic Drugs | -2.62% | +6.79% | +27.40% | +11.13% | -69.30% | 1.23B |  | |  |
- Stock Market
- Stocks
- VSTM Stock
- Charts Verastem, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
